Giovanni Caforio net worth and biography

Giovanni Caforio Biography and Net Worth

Giovanni Caforio, M.D. has been chief executive officer of Bristol Myers Squibb since May 2015 and has been serving on the company’s Board of Directors since June 2014. In May 2017, he assumed the role of chairman of the board.

As CEO, Giovanni has led the company’s focus on researching and developing transformational medicines, which includes a leading portfolio of immunotherapies that are fundamentally changing the way cancer is treated. Under his leadership, BMS is evolving its operating model, in order to increase speed and competitiveness.

With a background as a physician, Giovanni has helped strengthen the company’s patient-focused culture -- one driven by innovation, speed, accountability and passion. As a leader, he is focused on the business value of a company culture that promotes and rewards diversity and inclusion.

Prior to becoming CEO, Giovanni served as chief operating officer with responsibility for leading a fully integrated worldwide commercial organization and the companywide functions of Enterprise Services and Global Manufacturing & Supply. This was preceded by his work as the company’s chief commercial officer.

Giovanni joined Bristol Myers Squibb in 2000 as vice president and general manager, Italy, in the Worldwide Medicines Group. He assumed added responsibility for Greece and Israel in 2001, and for South East Europe in 2003. In 2004, he was appointed senior vice president, European Marketing and Brand Commercialization. In 2007, he relocated to the US to assume the role of senior vice president, U.S. Oncology. In 2010, he was named senior vice president, Global Commercialization, Oncology and Immunology, before becoming president of the company’s U.S. organization in 2011. Prior to joining Bristol Myers Squibb, Giovanni spent 12 years with Abbott Laboratories in a number of leadership positions.

Born and educated in Italy, Giovanni received his M.D. from the University of Rome.

What is Giovanni Caforio's net worth?: The estimated net worth of Giovanni Caforio is at least $10.59 million as of February 6th, 2023. Dr. Caforio owns 236,104 shares of Bristol-Myers Squibb stock worth more than $10,591,625 as of April 26th. This net worth evaluation does not reflect any other investments that Dr. Caforio may own. Learn More about Giovanni Caforio's net worth.
How do I contact Giovanni Caforio?: The corporate mailing address for Dr. Caforio and other Bristol-Myers Squibb executives is 430 E. 29TH STREET 14 FLOOR, NEW YORK NY, 10016. Bristol-Myers Squibb can also be reached via phone at (212) 546-4000 and via email at [email protected]. Learn More on Giovanni Caforio's contact information.
Has Giovanni Caforio been buying or selling shares of Bristol-Myers Squibb?: Giovanni Caforio has not been actively trading shares of Bristol-Myers Squibb during the last quarter. Most recently, Giovanni Caforio sold 240,000 shares of the business's stock in a transaction on Monday, February 6th. The shares were sold at an average price of $74.65, for a transaction totalling $17,916,000.00. Following the completion of the sale, the chief executive officer now directly owns 236,104 shares of the company's stock, valued at $17,625,163.60. Learn More on Giovanni Caforio's trading history.
Who are Bristol-Myers Squibb's active insiders?: Bristol-Myers Squibb's insider roster includes Mark Alles (CEO), Christopher Boerner (EVP), Giovanni Caforio (CEO), Adam Dubow (SVP), Joseph Eid (SVP), John Elicker (EVP), David Elkins (CFO), Sandra Leung (EVP), Dinesh Paliwal (Director), Robert Plenge (EVP), Ann Powell (EVP), Theodore Samuels, II (Director), Karen Santiago (SVP), Louis Schmukler (EVP), Rupert Vessey (EVP), and Paul von Autenried (EVP). Learn More on Bristol-Myers Squibb's active insiders.
Are insiders buying or selling shares of Bristol-Myers Squibb?: During the last year, Bristol-Myers Squibb insiders bought shares 3 times. They purchased a total of 13,571 shares worth more than $672,994.06. During the last year, insiders at the biopharmaceutical company sold shares 3 times. They sold a total of 69,103 shares worth more than $4,525,215.08. The most recent insider tranaction occured on December, 5th when CEO Christopher S Boerner bought 2,000 shares worth more than $99,560.00. Insiders at Bristol-Myers Squibb own 0.1% of the company. Learn More about insider trades at Bristol-Myers Squibb.
Information on this page was last updated on 12/5/2023.

Giovanni Caforio Insider Trading History at Bristol-Myers Squibb

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/6/2023	Sell	240,000	$74.65	$17,916,000.00	236,104
9/20/2022	Sell	25,000	$69.71	$1,742,750.00	476,104
9/15/2022	Sell	50,000	$71.84	$3,592,000.00	501,104
6/13/2022	Sell	30,000	$74.04	$2,221,200.00	551,104
3/21/2022	Sell	25,000	$71.52	$1,788,000.00
2/24/2022	Sell	30,000	$67.00	$2,010,000.00
9/20/2021	Sell	25,000	$60.64	$1,516,000.00
3/22/2021	Sell	25,000	$62.20	$1,555,000.00	528,980
8/31/2020	Sell	39,840	$62.70	$2,497,968.00	445,584
5/3/2016	Sell	34,594	$71.31	$2,466,898.14	132,263
2/17/2016	Sell	12,040	$63.58	$765,503.20	76,738
9/15/2014	Sell	26,691	$49.87	$1,331,080.17
2/24/2014	Sell	41,563	$54.44	$2,262,689.72	49,753
5/31/2013	Sell	10,538	$47.06	$495,918.28
5/23/2013	Sell	26,647	$46.29	$1,233,489.63
2/27/2013	Sell	12,150	$37.08	$450,522.00

Giovanni Caforio Buying and Selling Activity at Bristol-Myers Squibb

Bristol-Myers Squibb Company Overview

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Today's Range

Now: $44.86

$44.34

$45.37

50 Day Range

MA: $51.03

$44.68

$54.40

2 Week Range

Now: $44.86

$44.34

$69.10

Volume

21,279,666 shs

Average Volume

15,968,238 shs

Market Capitalization

$90.92 billion

P/E Ratio

11.62

Dividend Yield

4.91%

Beta

0.39

Better than Bitcoin? The Biotech Stock with 46,751% Potential

From Behind the Markets | Ad

4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.

Get the name of the stock here >>>